Expression Of HSP90Andanalysis Of Associated Factors In Multiple Myeloma

Objective：To evaluate the expression of HSP90in peripheral blood of multiple myelomapatients and its potential correlations with clinical characteristics, efficacy andoutcomes of multiple myeloma.Methods：A total of58MM patients were recruited from the hematology department ofSecond Affiliated Hospital of Nanchang University from September2012toSeptember2013, and30healthy volunteers were included as control counterparts.Patients with active infections and other malignant diseases were excluded. ELISAwas used to detect the plasma expression level of HSP90, and analyze the possiblerelationships between HSP90expression and clinical characteristics of MM patients,including age, sex, ISS stage, MM types, globulin, immunoglobulin, light chain,M-protein, bone marrow plasma cell proportion, β2-microglobulin and therapeuticregimens.Results：1. The expression level of HSP90in MM patients is significantly higher thanthat in normal controls（325.205±75.942ng/ml vs.85.401±11.261ng/ml, P<0.05）.2. Patients with new-diagnosed MM had similar HSP90expression as comparedto those with relapsed or refractory MM (405.251±43.186ng/ml vs.396.271±58.308ng/ml, P>0.05). However, patients with effective treatment of MM had strikinglylower HSP90expression compared with those new-diagnosed MM and relapsed orrefractory MM, respectively (273.354±51.333ng/ml vs.405.251±43.186ng/ml,P<0.05;273.354±51.333ng/ml vs.396.271±58.308ng/ml, P<0.05).3. The expression level of HSP90in MM patients with bortezomib-basedtreatment regimens reduced more significantly as compared to those nonbortezomib-based treatment regimens (P<0.05). 4. The expression level of HSP90in MM patients increased with ISS stage（P<0.05）.5. The expression level of HSP90had significantly positive correlations withbone marrow plasma cell proportion, globulin, immunoglobulin, M-protein,β2-microglobulin and light chain of MM patients（r>0.5, p<0.05）.6. The expression level of HSP90in MM patients had no correlations with age,sex and MM types（P>0.05）.Conclusion：The results showed that expression of secreted HSP90in MM patients is higherthan those in health controls, and patients with bortezomib-based treatment regimenshad lower HSP90levels, which suggests that HSP90may play an important role inthe occurrence and development of MM. In addition, HSP90is positively associatedwith ISS stage, bone marrow plasma cell proportion, globulin, immunoglobulin,M-protein, β2-microglobulin and light chain in MM patients, which suggests thatHSP90may contribute to judge the clinical course, efficacy and prognosis of MMpatients. Moreover, HSP90might even as a new therapeutic target of MM. Studyfurther need to be performed regarding effect of HSP90on mechanism of MM.